ePROficiency^TM 2009 Webinar Abstracts

Improving Measure Sensitivity in Early Stage Research
Based on regulatory guidance, Phase II is the appropriate time to develop and validate PRO measures, making ePRO a logical fit earlier in the clinical development lifecycle. This session will cover the advantages of incorporating electronic PRO capture methods in Phase II or early stage development studies.

Thursday, June 18 - 10 AM EST
Saul Shiffman, PhD, Chief Science Officer
invivodata, inc.